Great Basin Scientific — Investor Presentation (July 2017)
22 slides from Great Basin Scientific's investor presentation, Jul 7, 2017
Slide 1: The Power of Information
Insert Section Title The Power of Information July 7, 2017 OTCQB: GBSN
Slide 2: Regarding forward-looking statements
Insert Section Title All statements in this presentation that are not statements of historical fact are forward - looking statements, including stateme nts about any of the following: any projections of earnings, revenue, sales, profit margins, cash, working capital, or any other financial terms; th
Slide 3: The Company
Insert Section Title The Company ▪ We are the only provider of low - and mid - plex systems in the molecular diagnostics market for infectious disease ▪ Low - cost, ASP - focused model improves the reimbursement result for customers, making our system more attractive than those of many of our compet
Slide 4: Expanded Menu Driving Pipeline of New Business
Insert Section Title $107,172 $618,020 $1,406,740 $105,192 $980,044 $2,122,968 $446,628 $667,524 $1,512,498 Q3 2016 Q4 2016 As of 6/22/17 Total Expected Revenue of Sites in Evaluation Scheduled Active Evals Onboarding • Expected revenue from evaluations, scheduled evaluations and onboarding accounts
Slide 5: Expected Average Customer Size has Increased Rapidly
Insert Section Title Expected Average Customer Size has Increased 5 Rapidly Growing New Customer A nnual R evenue Projections $7,260 $12,620 $16,740 $38,120 $47,866 $- $10,000 $20,000 $30,000 $40,000 $50,000 $60,000 1Q2016 2Q2016 3Q2016 4Q2016 1Q2017
Slide 6: Our Markets: MDx Testing Improves Patient Outcomes & Lowers Cost of Care
Insert Section Title Our Markets Problem ▪ Leading cause of morbidity & mortality ▪ Culture takes ~ 3 days for a result ▪ Increased cost, delayed treatment, higher patient risk MDx Testing Improves Patient Outcomes & Lowers Cost of Care Solution ▪ MDx reduces Time to Result to 1 day ▪ Length of stay
Slide 7: Our Tests Target an Estimated $1.75B Addressable U.S. Market
Insert Section Title Our Markets ▪ Gastro Intestinal Distress $800MM* ▪ Blood Sepsis $200MM ▪ Whooping Cough $250MM ▪ Group B Strep (Neo - natal Meningitis) $200MM ▪ Products in Development Pipeline $300MM+ 7 Our Tests Target an Estimated $1.75B Addressable U.S. Market * Company estimates
Slide 8: Great Basin's Affordable Solution Designed for Small-Medium Hospitals
Insert Section Title Our System Analyzer ▪ Works with all Great Basin assays ▪ Does not require special staffing to read results ▪ Small footprint – requires little bench space ▪ No CapEx , value proposition Cartridges ▪ Single - use, minimal steps to prep ▪ Up to 5 answers per specimen ▪ Same cartr
Slide 9: Highly Sensitive Multi-Plex Detection
Insert Section Title Our Technology ▪ First U.S. Patent issued 2013 ▪ $0.23 per chip ▪ Up to 64 target array ▪ Sensitivity for direct - from - specimen detection 9 Highly Sensitive Multi - Plex Detection
Slide 10: Our Product Offering
Insert Section Title Our Product Offering Great Basin Product Menu Commercially Available Products Launch Date • Toxigenic C. difficile Test November 2012 • Group B Streptococcus Test May 2015 • Shiga Toxin Direct Test September 2016 • Staph ID/R Blood Culture Panel October 2016 • Bordetella Direct
Slide 11: The Competition
Insert Section Title The Competition 11 Only Great Basin Offers a Single Capital Solution vs. Requiring Two Capital Expenditures from Two Vendors 1 - 2 pathogen tests that answer: “Is it X?” Lower Reimbursement Lower Cost C. diff MRSA Sexually transmitted disease 5 - 25 pathogen panels that answer:
Slide 12: The Competitive Advantages of Mid-Plex over Mega Panels
Insert Section Title Mid - Plex » 3 - 6 pathogens » Reasonable cost » Single syndrome per panel (leverages empirical diagnosis) » Cover 90% - 95% of likely cause of disease » Answers drive therapy Mega Panels » 10 - 25 pathogens in a single assay » High cost » Multi - syndromic (include more than on
Slide 13: The Mid-Plex to Mega Panel Difference
Insert Section Title The Mid - Plex to Mega Panel Difference 13 Stool Bacterial Pathogens Panel Competitive Analysis Comparative features Targets 5 (Bacterial) 22 (Bacterial, Viral, Protozoa) Panel pricing $60 - $75 $120 - $130 Reimbursement ~$134 to $290 ~$134 to $290* 2015 Payor r ejection rate 6.
Slide 14: Growing Clinical and Payor Resistance to Larger Panels
Insert Section Title Market Dynamics ▪ Palmetto Local Coverage Determination Draft ▪ Panel must be “reasonable and necessary” ▪ Targets must represent a common syndrome (i.e. truly syndromic) ▪ There must be broad applicability (pathogens found in only select populations not appropriate) ▪ Must aid
Slide 15: Great Basin Mid-Plex Meets Palmetto and Clinical Preference
Insert Section Title The Great Basin Mid - Plex Advantage x Contains only targets likely after physician provides empirical diagnosis x Targets represent a single syndromic group x No confusing, statistically unlikely or unnecessary information x Answers limited to those that guide patient therapy x
Slide 16: Great Basin's Low/Mid-Plex Advantage
Insert Section Title The Winning Solution 16 Great Basin’s Low/Mid - Plex Advantage Yes No Yes Yes Yes No Low - Plex Mid - Plex Low - Plex Low - Plex Mega - Plex Mega - Plex Low - Plex Multi - Plex No No Yes Yes Yes Yes Sample to Result Menu CapEx Required
Slide 17: What our customers are saying
Insert Section Title The Solution 17 What our customers are saying My techs were unanimous the Great Basin assays were easier to use than our current platform for CDIFF, GBS and MRSA. - Microbiology Supervisor I love this system. So easy to run and easy to adopt since we don’t have capital equipment
Slide 18: Commercially-Focused Management Team
Insert Section Title Commercially - Focused Management Team • Operational, transactional & commercialization expertise • Prior: CEO of Printelligent ; VP Sales/Marketing of Inari; Sr. VP Sales/Marketing of Megahertz • Creator of molecular diagnostic testing platforms, expertise in clinical microbiol
Slide 19: Board of Directors
Insert Section Title Board of Directors • Founding investor of GBSN; Chairman since inception • Founder track record, operations and transaction expertise • Co - founder of Megahertz, sold to US Robotics for $450M; angel investor & philanthropist. David Spafford Executive Chairman • GBSN director si
Slide 20: Capital Structure
Insert Section Title Capital Structure ▪ Common shares & equivalents outstanding – 11.6MM (incl. shares from Series K Warrants) ▪ No variable priced instruments ▪ $20.3 million Series A Convertible Note ▪ Convertible at $3.00 a share, no resets or variable rate conversions, 6.8 million shares ▪ Not
Slide 21: Investment Highlights
Insert Section Title Investment Highlights ▪ One of only 4 pure plays in infectious disease molecular diagnostics market ▪ Expanded menu and installed customer - base provide a strong foundation to accelerate revenue growth ▪ $5.05MM New Business Pipeline with historical 82% new customer conversion
Slide 22: Thank you
Insert Section Title Thank you
Great Basin Scientific — Investor Presentation (July 2017) on 6ix